Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02YKI
|
||||
Former ID |
DIB002902
|
||||
Drug Name |
PF-04995274
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 1 | [1] | ||
Company |
Pfizer Inc
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C23H32N2O6
|
||||
Canonical SMILES |
C1CN(CCC1COC2=NOC3=C2C(=CC=C3)OC4CCOC4)CC5(CCOCC5)O
|
||||
InChI |
1S/C23H32N2O6/c26-23(7-12-27-13-8-23)16-25-9-4-17(5-10-25)14-29-22-21-19(30-18-6-11-28-15-18)2-1-3-20(21)31-24-22/h1-3,17-18,26H,4-16H2/t18-/m1/s1
|
||||
InChIKey |
WLLOFQROROXOMO-GOSISDBHSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 4 receptor | Target Info | Agonist | [2] | |
KEGG Pathway | Calcium signaling pathway | ||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Serotonergic synapse | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
5HT4 type receptor mediated signaling pathway | |||||
PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | ||||
Reactome | Serotonin receptors | ||||
G alpha (s) signalling events | |||||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT01193062) Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274. U.S. National Institutes of Health. | ||||
REF 2 | Pharmacokinetics, safety and tolerability of PF04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease. Alzheimer's and Dementia. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.